Related Experiment Video
Updated: May 30, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Implantable cardioverter defibrillators and cardiac resynchronisation therapy
Johannes Holzmeister1, Christophe Leclercq
1Department of Cardiology and Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland. johannes.holzmeister@usz.ch
Insights
Cardiac resynchronisation therapy (CRT) improves outcomes for heart failure patients. Current guidelines recommend CRT for both symptomatic and mildly symptomatic patients, with ongoing research into expanded indications and optimization strategies.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Management
Background:
- Implantable cardioverter defibrillators and cardiac resynchronisation therapy (CRT) are standard treatments for heart failure.
- Evidence supports CRT benefits in symptomatic (NYHA class III) and mildly symptomatic (NYHA class II) heart failure patients.
Purpose of the Study:
- To critically assess landmark randomized clinical trials (REVERSE, MADIT-CRT, RAFT) on CRT.
- To discuss emerging indications for CRT, including specific patient subgroups and optimization.
Main Methods:
- Review and critical assessment of landmark randomized clinical trials.
- Discussion of evidence for expanded CRT indications and patient response.
Main Results:
- CRT is recommended for both NYHA class II and III heart failure patients.
- Evidence supports exploring CRT in patients with mildly reduced LVEF and narrow QRS.
Conclusions:
- CRT is a cornerstone in heart failure management for a broader patient population.
- Further research and optimization are crucial for non-responders and improving CRT efficacy.
Abstract:
Implantable cardioverter defibrillators and cardiac resynchronisation therapy (CRT) have become standard of care in modern treatment for heart failure. Results from trials have provided ample evidence that CRT, in addition to its proven benefits in patients with symptomatic heart failure (New York Heart Association [NYHA] class III), might also reduce morbidity and mortality in those with mildly symptomatic heart failure (NYHA class II). As a result, the 2010 European Society of Cardiology guidelines now recommend CRT for both patient populations. In this review we summarise and critically assess the landmark randomised clinical trials REVERSE, MADIT-CRT, and RAFT. Furthermore, we discuss the rationale and available evidence for other emerging indications of CRT, including its use in patients with a mildly reduced left ventricular ejection fraction (>35%), in those with a narrow QRS complex (≤120 ms), and in those with concomitant bradyarrhythmic pacemaker indications. We also focus on patients who do not respond to CRT, and on CRT optimisation.
More Related Videos
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Dysrhythmias VI: Management of Dysrhythmias
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiopulmonary Resuscitation III: AED Use
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...

